RNA Modifications: Current Understandings and Future Perspectives

Abstract

RNA modification has been established as a pivotal field in epitranscriptomics, representing an emerging, dynamic, and precise regulatory layer in gene expression control. N6-methyladenosine (m⁶A), the most prevalent internal RNA modification, is critical for post-transcriptional regulation of RNA stability, translation, and degradation. In addition to m⁶A, RNA contains a number of other modifications that play important regulatory roles in RNA metabolism, transport, translation, and stability. Our review uses N4-acetylcytidine (ac4C) modification as a research paradigm to conduct a systematic review of the RNA modification research framework. This article begins with RNA modifications, then discusses several RNA modification-related regulatory enzymes before using ac4C as a detailed research example. Starting with the fundamental functions of ac4C in RNA modifications, it discusses its discovery history, the specific mechanisms of the key acetyltransferase N-acetyltransferase 10 (NAT10) in various RNA modifications, existing detection technologies, and the functional significance of ac4C modification under physiological and pathological conditions. This review systematically explains the multidimensional roles of RNA modifications, represented by ac4C, in health and disease. We point out that RNA modification-related regulatory enzymes, such as NAT10, can serve as prognostic biomarkers and therapeutic targets, thereby advancing disease mechanism research and improving clinical diagnosis and treatment.

Keywords

epigenetic modification / homeostasis / N4-acetylcytidine / pathophysiology / RNA modification

References

[1] S. Gerstberger, M. Hafner, and T. Tuschl, “A Census of Human RNA-Binding Proteins,” Nature Reviews Genetics 15, no. 12 (2014): 829–845.

[2] F. J. Slack and A. M. Chinnaiyan, “The Role of Non-Coding RNAs in Oncology,” Cell 179, no. 5 (2019): 1033–1055.

[3] M. Chen and C. M. Wong, “The Emerging Roles of N6-Methyladenosine (m6A) Deregulation in Liver Carcinogenesis,” Molecular Cancer 19, no. 1 (2020): 44.

[4] Y. Mei and X. Wang, “RNA Modification in mRNA Cancer Vaccines,” Clinical and Experimental Medicine 23, no. 6 (2023): 1917–1931.

[5] S. Nachtergaele and C. He, “Chemical Modifications in the Life of an mRNA Transcript,” Annual Review of Genetics 52 (2018): 349–372, https://doi.org/10.1146/annurev-genet-120417-031522.

[6] F. Morena, C. Argentati, M. Bazzucchi, C. Emiliani, and S. Martino, “Above the Epitranscriptome: RNA Modifications and Stem Cell Identity,” Genes (Basel) 9, no. 7 (2018): 329.

[7] Y. Liu, D. Yang, T. Liu, J. Chen, J. Yu, and P. Yi, “N6-Methyladenosine-Mediated Gene Regulation and Therapeutic Implications,” Trends in Molecular Medicine 29, no. 6 (2023): 454–467.

[8] M. Frye, B. T. Harada, M. Behm, and C. He, “RNA Modifications Modulate Gene Expression During Development,” Science 361, no. 6409 (2018): 1346–1349.

[9] H. Shi, J. Wei, and C. He, “Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers,” Molecular Cell 74, no. 4 (2019): 640–650.

[10] N. M. Martinez, A. Su, M. C. Burns, et al., “Pseudouridine Synthases Modify Human Pre-mRNA Co-Transcriptionally and Affect Pre-mRNA Processing,” Molecular Cell 82, no. 3 (2022): 645–659.

[11] M. Tegowski, M. N. Flamand, and K. D. Meyer, “scDART-seq Reveals Distinct m6A Signatures and mRNA Methylation Heterogeneity in Single Cells,” Molecular Cell 82, no. 4 (2022): 868–878.

[12] Z. Gu, L. Zou, X. Pan, et al., “The Role and Mechanism of NAT10-Mediated ac4C Modification in Tumor Development and Progression,” MedComm 5, no. 12 (2024): e70026.

[13] D. Arango, D. Sturgill, N. Alhusaini, et al., “Acetylation of Cytidine in mRNA Promotes Translation Efficiency,” Cell 175, no. 7 (2018): 1872–1886.

[14] X. Lihua, Z. Xiaolin, C. Wenyu, L. Jianghua, Z. Xuyu, and C. Ling, “Mechanisms of NAT10 as ac4C Writer in Diseases,” Molecular Therapy—Nucleic Acids 32 (2023): 359–368, https://kns.cnki.net/kcms2/article/abstract?v=WOgJpqC0z4ZeNUDPsb6e4B_-m6RkDWCMiOZJByoYKJnt8zq9UAV6u7jQgDtr8CrTuqcPlg1SNOoJxTL5u2l_mh6BhPdJ8qddeYqa4mcRPovCkYMOCmQfgpqkA-PbXw8UWEvgbdSGxc6VPCdNrcT59w==&uniplatform=NZKPT&language=gb.

[15] S. Ito, S. Horikawa, T. Suzuki, et al., “Human NAT10 Is an ATP-Dependent RNA Acetyltransferase Responsible for N4-Acetylcytidine Formation in 18 S Ribosomal RNA (rRNA),” Journal of Biological Chemistry 289, no. 52 (2014): 35724–35730.

[16] S. Sharma, J. L. Langhendries, P. Watzinger, P. Kötter, K. D. Entian, and D. L. J. Lafontaine, “Yeast Kre33 and Human NAT10 Are Conserved 18S rRNA Cytosine Acetyltransferases That Modify tRNAs Assisted by the Adaptor Tan1/THUMPD1,” Nucleic Acids Research 43, no. 4 (2015): 2242–2258.

[17] T. Wang, S. Kong, M. Tao, and S. Ju, “The Potential Role of RNA N6-Methyladenosine in Cancer Progression,” Molecular Cancer 19, no. 1 (2020): 88.

[18] R. Liu, Z. Wubulikasimu, R. Cai, et al., “NAT10-Mediated N4-Acetylcytidine mRNA Modification Regulates Self-Renewal in Human Embryonic Stem Cells,” Nucleic Acids Research 51, no. 16 (2023): 8514–8531.

[19] L. Wang, Y. Tao, J. Zhai, M. Xue, C. Zheng, and H. Hu, “The Emerging Roles of ac4C Acetylation “Writer” NAT10 in Tumorigenesis: A Comprehensive Review,” International Journal of Biological Macromolecules 254, no. pt. 2 (2024): 127789.

[20] Z. Zhenbiao, X. Xiaowei, H. Shisi, and T. Yuanyuan, “NAT10 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells by Mediating N4-Acetylcytidine Modification of Gremlin 1,” Stem Cells International 2021 (2021): 8833527, https://kns.cnki.net/kcms2/article/abstract?v=WOgJpqC0z4YKweGoehJ3gah-Mbl2xkOf1aH98iur0OJrJ3wCnmUBR-d_e52jS5lxiFtdqWFsjqbaX0VaTs8a-8Ecvf45za96XXvsVSvycNqBGoONxCWETXJO2Mpbi5RxDKG4P9m4O9BRy4PXrCx3SQ==&uniplatform=NZKPT&language=gb.

[21] S. H. Boo and Y. K. Kim, “The Emerging Role of RNA Modifications in the Regulation of mRNA Stability,” Experimental & Molecular Medicine 52, no. 3 (2020): 400–408.

[22] K. D. Meyer and S. R. Jaffrey, “Rethinking m6A Readers, Writers, and Erasers,” Annual Review of Cell and Developmental Biology 33 (2017): 319–342.

[23] D. Chen, X. Gu, Y. Nurzat, et al., “Writers, Readers, and Erasers RNA Modifications and Drug Resistance in Cancer,” Molecular cancer 23, no. 1 (2024): 178.

[24] A. Zhao, H. Zhou, J. Yang, M. Li, and T. Niu, “Epigenetic Regulation in Hematopoiesis and Its Implications in the Targeted Therapy of Hematologic Malignancies,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 71.

[25] S. Zaccara, R. J. Ries, and S. R. Jaffrey, “Reading, Writing and Erasing mRNA Methylation,” Nature Reviews Molecular Cell Biology 20, no. 10 (2019): 608–624.

[26] G. Wei, “RNA m6A Modification, Signals for Degradation or Stabilisation?,” Biochemical Society Transactions 52, no. 2 (2024): 707–717.

[27] X. Wang, B. S. Zhao, I. A. Roundtree, et al., “N(6)-Methyladenosine Modulates Messenger RNA Translation Efficiency,” Cell 161, no. 6 (2015): 1388–1399.

[28] Y. Li, H. Jin, Q. Li, L. Shi, Y. Mao, and L. Zhao, “The Role of RNA Methylation in Tumor Immunity and Its Potential in Immunotherapy,” Molecular Cancer 23, no. 1 (2024): 130.

[29] C. Xu, J. Zhang, J. Zhang, and B. Liu, “SIRT7 is a Deacetylase of N4-Acetylcytidine on Ribosomal RNA,” Genome Instability & Disease 2, no. 4 (2021): 253–260.

[30] N. Guzzi, M. Cieśla, P. C. T. Ngoc, et al., “Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells,” Cell 173, no. 5 (2018): 1204–1216.

[31] M. Madej, P. C. T. Ngoc, S. Muthukumar, et al., “PUS10-Induced tRNA Fragmentation Impacts Retrotransposon-Driven Inflammation,” Cell Reports 44, no. 6 (2025): 115735.

[32] K. D. Reddy, D. Xenaki, I. M. Adcock, B. G. G. Oliver, and R. Zakarya, “Epigenetic Inhibitors Differentially Impact TGF-β1 Signaling Cascades in COPD Airway Smooth Muscle Cells,” Cells 14, no. 1 (2024): 31.

[33] B. Wang, D. Shi, S. Yang, et al., “Mitochondrial tRNA Pseudouridylation Governs Erythropoiesis,” Blood 144, no. 6 (2024): 657–671.

[34] Z. Shi, S. Jin, X. Liu, et al., “The Epigenetic Regulatory Network of Long Noncoding RNAs in Hepatocellular Carcinoma,” Genes Disease 12, no. 5 (2025): 101534.

[35] J. M. Thomas, C. A. Briney, K. D. Nance, et al., “A Chemical Signature for Cytidine Acetylation in RNA,” Journal of the American Chemical Society 140, no. 40 (2018): 12667–12670.

[36] R. Karthiya, S. M. Wasil, and P. Khandelia, “Emerging Role of N4-Acetylcytidine Modification of RNA in Gene Regulation and Cellular Functions,” Molecular Biology Reports 47, no. 11 (2020): 9189–9199.

[37] T. Igo-Kemenes and H. G. Zachau, “On the Specificity of the Reduction of Transfer Ribonucleic Acids With Sodium Borohydride,” European Journal of Biochemistry 10, no. 3 (1969): 549–556.

[38] J. Thomale and G. Nass, “Increasing Urinary Levels of Modified Nucleosides and Bases During Tumor Development in Mice,” Recent Results in Cancer Research 84 (1983): 378–387.

[39] N. Zhang, S. Shi, T. Z. Jia, et al., “A General LC-MS-Based RNA Sequencing Method for Direct Analysis of Multiple-Base Modifications in RNA Mixtures,” Nucleic Acids Research 47, no. 20 (2019): e125.

[40] G. L. Glish and R. W. Vachet, “The Basics of Mass Spectrometry in the Twenty-First Century,” Nature Reviews Drug Discovery 2, no. 2 (2003): 140–150.

[41] S. H. Choi and K. D. Meyer, “Acetylation Takes Aim at mRNA,” Nature Structural & Molecular Biology 25, no. 12 (2018): 1067–1068.

[42] A. Sas-Chen, J. M. Thomas, D. Matzov, et al., “Dynamic RNA Acetylation Revealed by Quantitative Cross-Evolutionary Mapping,” Nature 583, no. 7817 (2020): 638–643.

[43] Q. Wang, Y. Du, S. Yan, et al., “Single-Cell Imaging of N4-Acetylcytidine-Modified RNA Using Fluorine Metabolic Labeling Mediated Proximity Ligation Assay,” Nucleic Acids Research 53, no. 10 (2025): gkaf464.

[44] S. Ito, Y. Akamatsu, A. Noma, et al., “A Single Acetylation of 18 S rRNA Is Essential for Biogenesis of the Small Ribosomal Subunit in Saccharomyces cerevisiae,” Journal of Biological Chemistry 289, no. 38 (2014): 26201–26212.

[45] R. Wetzel, J. Kohli, F. Altruda, and D. Söll, “Identification and Nucleotide Sequence of the Sup8-e UGA-Suppressor Leucine tRNA From Schizosaccharomyces pombe,” Molecular & General Genetics 172, no. 2 (1979): 221–228.

[46] C. W. Gehrke, K. C. Kuo, G. E. Davis, R. D. Suits, T. P. Waalkes, and E. Borek, “Quantitative High-Performance Liquid Chromatography of Nucleosides in Biological Materials,” Journal of Chromatography 150, no. 2 (1978): 455–476.

[47] I. R. Corrêa, E. J. Wolf, E. Yigit, and S. H. Chan, “Ribonucleases for Sequencing and Characterization of RNA by LC-MS,” in RNA Structure and Function (Springer, 2023), accessed September 5, 2024, https://link.springer.com/chapter/10.1007/978-3-031-36390-0_27.

[48] S. Sharma, J. L. Langhendries, and P. Watzinger, “Yeast Kre33 and Human NAT10 are Conserved 18S rRNA Cytosine Acetyltransferases That Modify tRNAs Assisted by the Adaptor Tan1/THUMPD1,” Nucleic Acids Research 43, no. 4 (2015): 2242–2258, https://doi.org/10.1093/nar/gkv075.

[49] J. M. Thomas, K. M. Bryson, and J. L. Meier, “Nucleotide Resolution Sequencing of N4-Acetylcytidine in RNA,” Methods in Enzymology 621 (2019): 31–51.

[50] S. Thalalla Gamage, A. Sas-Chen, S. Schwartz, and J. L. Meier, “Quantitative Nucleotide Resolution Profiling of RNA Cytidine Acetylation by ac4C-seq,” Nature Protocols 16, no. 4 (2021): 2286–2307.

[51] D. Sturgill, D. Arango, and S. Oberdoerffer, “Protocol for Base Resolution Mapping of ac4C Using RedaC:T-seq,” STAR Protocols 3, no. 4 (2022): 101858.

[52] D. Arango, D. Sturgill, and S. Oberdoerffer, “Immunoprecipitation and Sequencing of Acetylated RNA,” Bio-Protocols 9, no. 12 (2019): e3278.

[53] S. Yan, Z. Lu, W. Yang, et al., “Antibody-Free Fluorine-Assisted Metabolic Sequencing of RNA N4-Acetylcytidine,” Journal of the American Chemical Society 145, no. 40 (2023): 22232–22242.

[54] W. Zhao, Y. Zhou, Q. Cui, and Y. Zhou, “PACES: Prediction of N4-Acetylcytidine (ac4C) Modification Sites in mRNA,” Scientific Reports 9, no. 1 (2019): 11112.

[55] W. Alam, H. Tayara, and K. T. Chong, “XG-ac4C: Identification of N4-Acetylcytidine (ac4C) in mRNA Using eXtreme Gradient Boosting With Electron-Ion Interaction Pseudopotentials,” Scientific Reports 10, no. 1 (2020): 20942.

[56] C. Wang, Y. Ju, Q. Zou, and C. Lin, “DeepAc4C: A Convolutional Neural Network Model With Hybrid Features Composed of Physicochemical Patterns and Distributed Representation Information for Identification of N4-Acetylcytidine in mRNA,” Bioinformatics 38, no. 1 (2021): 52–57.

[57] G. Zhang, W. Luo, J. Lyu, Z. G. Yu, and G. Huang, “CNNLSTMac4CPred: A Hybrid Model for N4-Acetylcytidine Prediction,” Interdisciplinary Science 14, no. 2 (2022): 439–451.

[58] J. Jia, Z. Wei, and X. Cao, “EMDL-ac4C: Identifying N4-Acetylcytidine Based on Ensemble Two-Branch Residual Connection DenseNet and Attention,” Frontiers in Genetics 14 (2023): 1232038, https://doi.org/10.3389/fgene.2023.1232038.

[59] J. Jia, X. Cao, and Z. Wei, “DLC-ac4C: A Prediction Model for N4-Acetylcytidine Sites in Human mRNA Based on DenseNet and Bidirectional LSTM Methods,” Current Genomics 24, no. 3 (2023): 171–186.

[60] D. Liu, Z. Liu, Y. Xia, Z. Wang, J. Song, and D. J. Yu, “TransC-ac4C: Identification of N4-Acetylcytidine (ac4C) Sites in mRNA Using Deep Learning,” IEEE/ACM Transactions on Computational Biology and Bioinformatics 21, no. 5 (2024): 1403–1412, https://doi.org/10.1109/TCBB.2024.3386972.

[61] F. L. Lai and F. Gao, “LSA-ac4C: A Hybrid Neural Network Incorporating Double-Layer LSTM and Self-Attention Mechanism for the Prediction of N4-Acetylcytidine Sites in Human mRNA,” International Journal of Biological Macromolecules 253, no. pt. 3 (2023): 126837.

[62] J. Yuan, Z. Wang, Z. Pan, A. Li, Z. Zhang, and F. Cui, “DPNN-ac4C: A Dual-Path Neural Network With Self-Attention Mechanism for Identification of N4‑Acetylcytidine (ac4C) in mRNA,” Bioinformatics 40, no. 11 (2024): btae625.

[63] R. Liu, Y. Zhang, Q. Wang, and X. Zhang, “TransAC4C - A Novel Interpretable Architecture for Multi-Species Identification of N4-Acetylcytidine Sites in RNA With Single-Base Resolution,” Brief Bioinformatics 25, no. 3 (2024): bbae200, https://doi.org/10.1093/bib/bbae200.

[64] F. Li, J. Zhang, K. Li, et al., “GANSamples-ac4C: Enhancing ac4C Site Prediction via Generative Adversarial Networks and Transfer Learning,” Analytical Biochemistry 689 (2024): 115495.

[65] Z. Li, B. Jin, and J. Fang, “MetaAc4C: A Multi-Module Deep Learning Framework for Accurate Prediction of N4-Acetylcytidine Sites Based on Pre-Trained Bidirectional Encoder Representation and Generative Adversarial Networks,” Genomics 116, no. 1 (2024): 110749.

[66] W. He, Y. Han, Y. Zuo, Y. Bai, and F. Guo, “NBCR-ac4C: A Deep Learning Framework Based on Multivariate BERT for Human mRNA N4-Acetylcytidine Sites Prediction,” Journal of Chemical Information and Modeling 64, no. 20 (2024): 8074–8081, https://doi.org/10.1021/acs.jcim.4c01415.

[67] Y. Jia, Z. Zhang, S. Yan, Q. Zhang, L. Wei, and F. Cui, “Voting-ac4C: Pre-Trained Large RNA Language Model Enhances RNA N4-Acetylcytidine Site Prediction,” International Journal of Biological Macromolecules 282 (2024): 136940.

[68] W. Su, X. Q. Xie, X. W. Liu, et al., “iRNA-ac4C: A Novel Computational Method for Effectively Detecting N4-Acetylcytidine Sites in Human mRNA,” International Journal of Biological Macromolecules 227 (2023): 1174–1181.

[69] N. T. Pham, A. T. Terrance, Y. J. Jeon, R. Rakkiyappan, and B. Manavalan, “ac4C-AFL: A High-Precision Identification of Human mRNA N4-Acetylcytidine Sites Based on Adaptive Feature Representation Learning,” Molecular Therapy—Nucleic Acids 35, no. 2 (2024): 102192.

[70] L. L. Lou, W. R. Qiu, Z. Liu, Z. C. Xu, X. Xiao, and S. F. Huang, “Stacking-ac4C: An Ensemble Model Using Mixed Features for Identifying n4-Acetylcytidine in mRNA,” Frontiers in Immunology 14 (2023): 1267755.

[71] R. Lu, J. Qiao, K. Li, et al., “ERNIE-ac4C: A Novel Deep Learning Model for Effectively Predicting N4-Acetylcytidine Sites,” Journal of Molecular Biology 437, no. 6 (2025): 168978.

[72] M. Yi, F. Zhou, and Y. Deng, “STM-ac4C: A Hybrid Model for Identification of N4-Acetylcytidine (ac4C) in Human mRNA Based on Selective Kernel Convolution, Temporal Convolutional Network, and Multi-Head Self-Attention,” Frontiers in Genetics 15 (2024): 1408688.

[73] Y. Wu, W. Shao, S. Liu, et al., “Simultaneous Profiling of ac4C and m5C Modifications From Nanopore Direct RNA Sequencing,” International Journal of Biological Macromolecules 305, no. pt 1 (2025): 140863.

[74] J. Jia, Z. Wei, and X. Cao, “EMDL-ac4C: Identifying N4-Acetylcytidine Based on Ensemble Two-Branch Residual Connection DenseNet and Attention,” Frontiers in Genetics 14 (2023): 1232038.

[75] L. Yao, P. Xie, D. Dong, et al., “Caps-ac4C: An Effective Computational Framework for Identifying N4-Acetylcytidine Sites in Human mRNA Based on Deep Learning,” Journal of Molecular Biology 437, no. 6 (2025): 168961.

[76] M. L. Bortolin-Cavaillé, A. Quillien, S. Thalalla Gamage, et al., “Probing Small Ribosomal Subunit RNA Helix 45 Acetylation Across Eukaryotic Evolution,” Nucleic Acids Research 50, no. 11 (2022): 6284–6299.

[77] H. G. Zachau, D. Dütting, and H. Feldmann, “The Structures of Two Serine Transfer Ribonucleic Acids,” Hoppe Seylers Zeitschrift fur Physiologische Chemie 347, no. 4 (1966): 212–235.

[78] M. Staehelin, H. Rogg, B. C. Baguley, T. Ginsberg, and W. Wehrli, “Structure of a Mammalian Serine tRNA,” Nature 219, no. 5161 (1968): 1363–1365.

[79] S. Kowalski, T. Yamane, and J. R. Fresco, “Nucleotide Sequence of the “Denaturable” Leucine Transfer RNA From Yeast,” Science 172, no. 3981 (1971): 385–387.

[80] J. Kruppa and H. G. Zachau, “Multiplicity of Serine-Specific Transfer RNAs of Brewer's and Baker's Yeast,” Biochimica et Biophysica Acta 277, no. 3 (1972): 499–512.

[81] Z. Oashi, K. Murao, T. Yahagi, D. L. Von Minden, J. A. McCloskey, and S. Nishimura, “Characterization of C + Located in the First Position of the Anticodon of Escherichia coli tRNA Met as N 4-Acetylcytidine,” Biochimica et Biophysica Acta 262, no. 2 (1972): 209–213.

[82] K. Tsai, A. A. Jaguva Vasudevan, C. Martinez Campos, A. Emery, R. Swanstrom, and B. R. Cullen, “Acetylation of Cytidine Residues Boosts HIV-1 Gene Expression by Increasing Viral RNA Stability,” Cell Host & Microbe 28, no. 2 (2020): 306–312.

[83] A. P. G. Silva, R. T. Byrne, M. Chechik, C. Smits, D. G. Waterman, and A. A. Antson, “Expression, Purification, Crystallization and Preliminary X-Ray Studies of the TAN1 Orthologue From Methanothermobacter thermautotrophicus,” Acta Crystallographica Section F Structural Biology and Crystallization Communications 64, no. pt. 11 (2008): 1083–1086.

[84] Y. Ikeuchi, K. Kitahara, and T. Suzuki, “The RNA Acetyltransferase Driven by ATP Hydrolysis Synthesizes N4-Acetylcytidine of tRNA Anticodon,” EMBO Journal 27, no. 16 (2008): 2194–2203.

[85] B. V. Kumbhar, A. D. Kamble, and K. D. Sonawane, “Conformational Preferences of Modified Nucleoside N(4)-Acetylcytidine, ac4C Occur at “Wobble” 34th Position in the Anticodon Loop of tRNA,” Cell Biochemistry and Biophysics 66, no. 3 (2013): 797–816.

[86] L. Stern and L. H. Schulman, “The Role of the Minor Base N4-Acetylcytidine in the Function of the Escherichia coli Noninitiator Methionine Transfer RNA,” Journal of Biological Chemistry 253, no. 17 (1978): 6132–6139.

[87] G. Kawai, T. Hashizume, T. Miyazawa, J. A. McCloskey, and S. Yokoyama, “Conformational Characteristics of 4-Acetylcytidine Found in tRNA,” Nucleic Acids Symposium Series 21 (1989): 61–62.

[88] M. J. O. Johansson and A. S. Byström, “The Saccharomyces cerevisiae TAN1 Gene Is Required for N4-Acetylcytidine Formation in tRNA,” RNA 10, no. 4 (2004): 712–719.

[89] Y. Fu, D. Dominissini, G. Rechavi, and C. He, “Gene Expression Regulation Mediated Through Reversible m⁶A RNA Methylation,” Nature Reviews Genetics 15, no. 5 (2014): 293–306.

[90] J. Zheng, Y. Tan, X. Liu, et al., “NAT10 Regulates Mitotic Cell Fate by Acetylating Eg5 to Control Bipolar Spindle Assembly and Chromosome Segregation,” Cell Death and Differentiation 29, no. 4 (2022): 846–860.

[91] S. R. Maran, A. B. Leite, G. G. Alves, et al., “Leishmania mexicana N-Acetyltransferease 10 Is Important for Polysome Formation and Cell Cycle Progression,” Molecular Microbiology 123, no. 1 (2025): 60–74.

[92] Z. Cui, C. Fu, D. Ai, et al., “NAT10 Regulates Zygotic Genome Activation and the Morula-to-Blastocyst Transition,” FASEB Journal 39, no. 5 (2025): e70444.

[93] D. Fu and K. Collins, “Purification of Human Telomerase Complexes Identifies Factors Involved in Telomerase Biogenesis and Telomere Length Regulation,” Molecular Cell 28, no. 5 (2007): 773–785.

[94] H. Liu, Y. Ling, Y. Gong, Y. Sun, L. Hou, and B. Zhang, “DNA Damage Induces N-Acetyltransferase NAT10 Gene Expression Through Transcriptional Activation,” Molecular and Cellular Biochemistry 300, no. 1–2 (2007): 249–258.

[95] Q. Shen, X. Zheng, M. A. McNutt, et al., “NAT10, a Nucleolar Protein, Localizes to the Midbody and Regulates Cytokinesis and Acetylation of Microtubules,” Experimental Cell Research 315, no. 10 (2009): 1653–1667.

[96] D. Larrieu, S. Britton, M. Demir, R. Rodriguez, and S. P. Jackson, “Chemical Inhibition of NAT10 Corrects Defects of Laminopathic Cells,” Science 344, no. 6183 (2014): 527–532.

[97] H. Zhang, W. Hou, H. L. Wang, et al., “GSK-3β-Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion,” Clinical Cancer Research 20, no. 17 (2014): 4717–4729.

[98] T. K. Debnath, N. S. Abell, Y. R. Li, S. K. Devanathan, E. Navedo, and B. Xhemalçe, “NAT10 and N4-Acetylcytidine Restrain R-Loop Levels and Related Inflammatory Responses,” Science Advances 11, no. 13 (2025): eads6144.

[99] T. Taniguchi, K. Miyauchi, Y. Sakaguchi, et al., “Acetate-Dependent tRNA Acetylation Required for Decoding Fidelity in Protein Synthesis,” Nature Chemical Biology 14, no. 11 (2018): 1010–1020.

[100] S. Thalalla Gamage, S. Howpay Manage, A. Sas-Chen, et al., “A Sequence-Specific RNA Acetylation Catalyst,” Nucleic Acids Research 53, no. 6 (2025): gkaf217.

[101] M. H. Dalhat, H. N. Altayb, M. I. Khan, and H. Choudhry, “Structural Insights of Human N-Acetyltransferase 10 and Identification of Its Potential Novel Inhibitors,” Scientific Reports 11, no. 1 (2021): 6051.

[102] Z. Zhao, J. Meng, R. Su, et al., “Epitranscriptomics in Liver Disease: Basic Concepts and Therapeutic Potential,” Journal of Hepatology 73, no. 3 (2020): 664–679.

[103] K. Xu, Y. Sun, B. Sheng, Y. Zheng, X. Wu, and K. Xu, “Role of Identified RNA N6-Methyladenosine Methylation in Liver,” Analytical Biochemistry 578 (2019): 45–50.

[104] L. Yang, S. Tian, X. Zheng, et al., “N6-Methyladenosine RNA Methylation in Liver Diseases: From Mechanism to Treatment,” Journal of Gastroenterology 58, no. 8 (2023): 718–733.

[105] X. Wang, Y. Ding, R. Li, et al., “N6-Methyladenosine of Spi2a Attenuates Inflammation and Sepsis-Associated Myocardial Dysfunction in Mice,” Nature Communications 14, no. 1 (2023): 1185.

[106] A. Castello, B. Fischer, K. Eichelbaum, et al., “Insights Into RNA Biology From an Atlas of Mammalian mRNA-Binding Proteins,” Cell 149, no. 6 (2012): 1393–1406.

[107] A. Alexandrov, M. R. Martzen, and E. M. Phizicky, “Two Proteins That Form a Complex Are Required for 7-Methylguanosine Modification of Yeast tRNA,” RNA 8, no. 10 (2002): 1253–1266.

[108] K. Li, J. Liu, X. Yang, Z. Tu, K. Huang, and X. Zhu, “Pan-Cancer Analysis of N4-Acetylcytidine Adaptor THUMPD1 as a Predictor for Prognosis and Immunotherapy,” Bioscience Report 41, no. 12 (2021): BSR20212300, https://doi.org/10.1042/BSR20212300.

[109] C. Yang, T. Wu, J. Zhang, et al., “Prognostic and Immunological Role of mRNA ac4C Regulator NAT10 in Pan-Cancer: New Territory for Cancer Research?,” Frontiers in Oncology 11 (2021): 630417.

[110] M. H. Dalhat, M. R. S. Mohammed, H. A. Alkhatabi, et al., “NAT10: An RNA Cytidine Transferase Regulates Fatty Acid Metabolism in Cancer Cells,” Clinical and Translational Medicine 12, no. 9 (2022): e1045.

[111] M. H. Dalhat, H. Choudhry, and M. I. Khan, “NAT10, an RNA Cytidine Acetyltransferase, Regulates Ferroptosis in Cancer Cells,” Antioxidants (Basel) 12, no. 5 (2023): 1116.

[112] F. Baidoun, K. Elshiwy, Y. Elkeraie, et al., “Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes,” Current Drug Targets 22, no. 9 (2021): 998–1009.

[113] T. A. Graham and A. Sottoriva, “Measuring Cancer Evolution From the Genome,” Journal of Pathology 241, no. 2 (2017): 183–191.

[114] M. R. Islam, S. Akash, M. M. Rahman, et al., “Colon Cancer and Colorectal Cancer: Prevention and Treatment by Potential Natural Products,” Chemico-Biological Interactions 368 (2022): 110170.

[115] H. Zhang, W. Shan, Z. Yang, et al., “NAT10 Mediated mRNA Acetylation Modification Patterns Associated With Colon Cancer Progression and Microsatellite Status,” Epigenetics 18, no. 1 (2023): 2188667.

[116] X. Zheng, Q. Wang, Y. Zhou, et al., “N-Acetyltransferase 10 Promotes Colon Cancer Progression by Inhibiting Ferroptosis Through N4-Acetylation and Stabilization of Ferroptosis Suppressor Protein 1 (FSP1) mRNA,” Cancer Communication (London) 42, no. 12 (2022): 1347–1366.

[117] S. Doll, F. P. Freitas, R. Shah, et al., “FSP1 is a Glutathione-Independent Ferroptosis Suppressor,” Nature 575, no. 7784 (2019): 693–698.

[118] L. P. Gao, T. D. Li, S. Z. Yang, H. M. Ma, X. Wang, and D. K. Zhang, “NAT10-Mediated ac4C Modification Promotes Stemness and Chemoresistance of Colon Cancer by Stabilizing NANOGP8,” Heliyon 10, no. 9 (2024): e30330.

[119] J. S. Whelan and L. E. Davis, “Osteosarcoma, Chondrosarcoma, and Chordoma,” Journal of Clinical Oncology 36, no. 2 (2018): 188–193.

[120] J. Gill and R. Gorlick, “Advancing Therapy for Osteosarcoma,” Nature Reviews Clinical Oncology 18, no. 10 (2021): 609–624.

[121] R. Zheng, S. Zhang, H. Zeng, et al., “Cancer Incidence and Mortality in China,” Journal of the National Cancer Center 2, no. 1 (2022): 1–9.

[122] P. S. Meltzer and L. J. Helman, “New Horizons in the Treatment of Osteosarcoma,” New England Journal of Medicine 385, no. 22 (2021): 2066–2076.

[123] N. C. Daw, A. J. Chou, N. Jaffe, et al., “Recurrent Osteosarcoma With a Single Pulmonary Metastasis: A Multi-Institutional Review,” British Journal of Cancer 112, no. 2 (2015): 278–282.

[124] H. B. Li, G. Huang, J. Tu, et al., “METTL14-Mediated Epitranscriptome Modification of MN1 mRNA Promote Tumorigenicity and All-Trans-Retinoic Acid Resistance in Osteosarcoma,” EBioMedicine 82 (2022): 104142.

[125] Z. Mei, Z. Shen, J. Pu, et al., “NAT10 Mediated ac4C Acetylation Driven m6A Modification via Involvement of YTHDC1-LDHA/PFKM Regulates Glycolysis and Promotes Osteosarcoma,” Cell Communication and Signaling 22, no. 1 (2024): 51.

[126] W. Zhang, J. Gao, L. Fan, et al., “ac4C Acetylation Regulates mRNA Stability and Translation Efficiency in Osteosarcoma,” Heliyon 9, no. 6 (2023): e17103.

[127] J. Gao, P. Xu, F. Wang, et al., “Revealing the Pharmacological Effects of Remodelin Against Osteosarcoma Based on Network Pharmacology, acRIP-seq and Experimental Validation,” Scientific Reports 14, no. 1 (2024): 3577.

[128] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[129] L. Liao, Y. He, S. J. Li, et al., “Lysine 2-Hydroxyisobutyrylation of NAT10 Promotes Cancer Metastasis in an ac4C-Dependent Manner,” Cell Research 33, no. 5 (2023): 355–371.

[130] J. N. Søndergaard, C. Sommerauer, I. Atanasoai, et al., “CCT3-LINC00326 Axis Regulates Hepatocarcinogenic Lipid Metabolism,” Gut 71, no. 10 (2022): 2081–2092.

[131] X. M. Yu, S. J. Li, Z. T. Yao, et al., “N4-Acetylcytidine Modification of lncRNA CTC-490G23.2 Promotes Cancer Metastasis Through Interacting With PTBP1 to Increase CD44 Alternative Splicing,” Oncogene 42, no. 14 (2023): 1101–1116.

[132] C. Jin, J. Gao, J. Zhu, Y. Ao, B. Shi, and X. Li, “Exosomal NAT10 From Esophageal Squamous Cell Carcinoma Cells Modulates Macrophage Lipid Metabolism and Polarization Through ac4C Modification of FASN,” Translational Oncology 45 (2024): 101934.

[133] W. Wei, S. Zhang, H. Han, et al., “NAT10-Mediated ac4C tRNA Modification Promotes EGFR mRNA Translation and Gefitinib Resistance in Cancer,” Cell Reports 42, no. 7 (2023): 112810.

[134] J. Liang, P. Zhai, G. Cheng, J. Han, and X. Song, “N-Acetyltransferase 10 Promotes Gastric Cancer Progression by Mediating the N4-Acetylcytidine Modification of Lactate Dehydrogenase A,” Journal of Biochemical and Molecular Toxicology 39, no. 3 (2025): e70227.

[135] Q. Yang, X. Lei, J. He, et al., “N4-Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/HIF-1α Positive Feedback Loop,” Advanced Science (Weinheim) 10, no. 23 (2023): e2300898.

[136] H. Yang and W. Xu, “STAT3 Promotes Peritoneal Metastasis of Gastric Cancer by Enhancing Mesothelial-Mesenchymal Transition,” Biological Chemistry 402, no. 6 (2021): 739–748.

[137] U. Demkow, “Neutrophil Extracellular Traps (NETs) in Cancer Invasion, Evasion and Metastasis,” Cancers (Basel) 13, no. 17 (2021): 4495.

[138] D. Liu, X. Yang, and X. Wang, “Neutrophil Extracellular Traps Promote Gastric Cancer Cell Metastasis via the NAT10-Mediated N4-Acetylcytidine Modification of SMYD2,” Cell Signalling 116 (2024): 111014.

[139] S. Song, B. Li, X. Jin, et al., “NAT10 Overexpression Promotes Tumorigenesis and Epithelial-Mesenchymal Transition Through AKT Pathway in Gastric Cancer,” Digestive Diseases and Sciences 69, no. 9 (2024): 3261–3275, https://doi.org/10.1007/s10620-024-08472-z.

[140] H. Zhang, R. Lu, J. Huang, et al., “N4-Acetylcytidine Modifies Primary microRNAs for Processing in Cancer Cells,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 73.

[141] Y. Yuan, N. Li, J. Zhu, C. Shao, X. Zeng, and D. Yi, “Role of NAT10-Mediated ac4C Acetylation of ENO1 mRNA in Glycolysis and Apoptosis in Non-Small Cell Lung Cancer Cells,” BMC Pulmonary Medicine 25, no. 1 (2025): 75.

[142] Q. Guo, W. Yu, J. Tan, et al., “Remodelin Delays Non-Small Cell Lung Cancer Progression by Inhibiting NAT10 via the EMT Pathway,” Cancer Medicine 13, no. 11 (2024): e7283.

[143] N. Xiao, H. Liu, R. Zhang, et al., “N-Acetyltransferase 10 Impedes EZH2/H3K27me3/GABARAP Axis Mediated Autophagy and Facilitates Lung Cancer Tumorigenesis Through Enhancing SGK2 mRNA Acetylation,” International Journal of Biological Macromolecules 297 (2025): 139823.

[144] H. Wang, B. Zhao, J. Zhang, et al., “N4-Acetylcytidine-Mediated CD2BP2-DT Drives YBX1 Phase Separation to Stabilize CDK1 and Promote Breast Cancer Progression,” Advanced Science (Weinheim) 12 (2025): e2411834, https://doi.org/10.1002/advs.202411834.

[145] J. Jin, Z. Tao, J. Cao, T. Li, and X. Hu, “DNA Damage Response Inhibitors: An Avenue for TNBC Treatment,” Biochimica et Biophysica Acta Reviews on Cancer 1875, no. 2 (2021): 188521.

[146] C. C. Zhao, X. Sun, J. Chen, and B. D. Geng, “NAT10-Mediated mRNA N4-Acetylcytidine Modification of MDR1 and BCRP Promotes Breast Cancer Progression,” Thoracic Cancer 15, no. 10 (2024): 820–829.

[147] X. Zhang, J. Zeng, J. Wang, et al., “Revealing the Potential Markers of N(4)-Acetylcytidine Through acRIP-seq in Triple-Negative Breast Cancer,” Genes (Basel) 13, no. 12 (2022): 2400.

[148] G. Li, X. Ma, S. Sui, et al., “NAT10/ac4C/JunB Facilitates TNBC Malignant Progression and Immunosuppression by Driving Glycolysis Addiction,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 278.

[149] S. Wang, Q. Li, Y. Wang, et al., “Peptidylprolyl Isomerase D Circular RNA Sensitizes Breast Cancer to Trastuzumab Through Remodeling HER2 N4-Acetylcytidine Modification,” Journal of Applied Genetics 65, no. 4 (2024): 797–807, https://doi.org/10.1007/s13353-024-00840-9.

[150] R. B. Perkins, N. Wentzensen, R. S. Guido, and M. Schiffman, “Cervical Cancer Screening: A Review,” JAMA 330, no. 6 (2023): 547–558.

[151] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 21820, https://doi.org/10.3322/caac.21820.

[152] X. Chen, Y. Hao, Y. Liu, et al., “NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer,” Advanced Science (Weinheim) 10, no. 32 (2023): e2302705.

[153] Y. Long, Y. Ren, Q. Wei, et al., “NAT10-Mediated RNA Acetylation Enhances HNRNPUL1 mRNA Stability to Contribute Cervical Cancer Progression,” International Journal of Medical Sciences 20, no. 8 (2023): 1079–1090.

[154] P. Liang, D. Zhou, J. Liao, W. Lai, X. Sheng, and Y. Wang, “N-Acetyltransferase 10 Promotes Cervical Cancer Progression via N4-Acetylation of SLC7A5 mRNA,” Frontiers in Bioscience (Landmark Edition) 30, no. 2 (2025): 26756.

[155] C. Zhang, L. Yuan, Q. Zou, et al., “CircMAST1 Inhibits Cervical Cancer Progression by Hindering the N4-Acetylcytidine Modification of YAP mRNA,” Cellular & Molecular Biology Letters 29, no. 1 (2024): 25.

[156] G. Wang, M. Zhang, Y. Zhang, et al., “NAT10-Mediated mRNA N4-Acetylcytidine Modification Promotes Bladder Cancer Progression,” Clinical and Translational Medicine 12, no. 5 (2022): e738.

[157] R. Xie, L. Cheng, M. Huang, et al., “NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer,” Cancer Research 83, no. 10 (2023): 1666–1683.

[158] A. Forner, M. Reig, and J. Bruix, “Hepatocellular Carcinoma,” Lancet 391, no. 10127 (2018): 1301–1314.

[159] H. Liu, L. Xu, S. Yue, et al., “Targeting N4-Acetylcytidine Suppresses Hepatocellular Carcinoma Progression by Repressing eEF2-Mediated HMGB2 mRNA Translation,” Cancer Communication (London) 44, no. 9 (2024): 1018–1041, https://doi.org/10.1002/cac2.12595.

[160] J. H. Kwon, J. Kim, J. Y. Park, et al., “Overexpression of High-Mobility Group Box 2 Is Associated With Tumor Aggressiveness and Prognosis of Hepatocellular Carcinoma,” Clinical Cancer Research 16, no. 22 (2010): 5511–5521.

[161] N. Xu, J. Zhuo, Y. Chen, et al., “Downregulation of N4-Acetylcytidine Modification in Myeloid Cells Attenuates Immunotherapy and Exacerbates Hepatocellular Carcinoma Progression,” British Journal of Cancer 130, no. 2 (2024): 201–212.

[162] Z. Xu, M. Zhu, L. Geng, et al., “Targeting NAT10 Attenuates Homologous Recombination via Destabilizing DNA:RNA Hybrids and Overcomes PARP Inhibitor Resistance in Cancers,” Drug Resistance Updates 81 (2025): 101241.

[163] W. L. da Costa, H. S. Tran Cao, and N. N. Massarweh, “Neoadjuvant Treatment for Patients with Localized Pancreatic Adenocarcinoma: Are We There Yet?,” JAMA Oncology 6, no. 8 (2020): 1163–1164.

[164] D. Xu, K. Huang, Y. Chen, F. Yang, C. Xia, and H. Yang, “Immune Response and Drug Therapy Based on ac4C-Modified Gene in Pancreatic Cancer Typing,” Frontiers in Immunology 14 (2023): 1133166.

[165] G. Zong, X. Wang, X. Guo, et al., “NAT10-Mediated AXL mRNA N4-Acetylcytidine Modification Promotes Pancreatic Carcinoma Progression,” Experimental Cell Research 428, no. 2 (2023): 113620.

[166] Y. Song and M. Cheng, “NAT10 Promotes Ovarian Cancer Cell Migration, Invasion, and Stemness via N4-Acetylcytidine Modification of CAPRIN1,” BMC Womens Health 25, no. 1 (2025): 54.

[167] Y. Liu, J. Li, J. Xu, et al., “m6A-Driven NAT10 Translation Facilitates Fatty Acid Metabolic Rewiring to Suppress Ferroptosis and Promote Ovarian Tumorigenesis Through Enhancing ACOT7 mRNA Acetylation,” Oncogene 43 (2024): 3498–3516, https://doi.org/10.1038/s41388-024-03185-z.

[168] Y. P. Chen, A. T. C. Chan, Q. T. Le, P. Blanchard, Y. Sun, and J. Ma, “Nasopharyngeal Carcinoma,” Lancet 394, no. 10192 (2019): 64–80.

[169] H. S. Zaher and R. Green, “Fidelity at the Molecular Level: Lessons From Protein Synthesis,” Cell 136, no. 4 (2009): 746–762.

[170] N. Anand, S. Murthy, G. Amann, et al., “Protein Elongation Factor EEF1A2 Is a Putative Oncogene in Ovarian Cancer,” Nature Genetics 31, no. 3 (2002): 301–305.

[171] M. K. Hassan, D. Kumar, S. A. Patel, and M. Dixit, “EEF1A2 Triggers Stronger ERK Mediated Metastatic Program in ER Negative Breast Cancer Cells Than in ER Positive Cells,” Life Sciences 262 (2020): 118553.

[172] S. Gong, H. Qiao, J. Y. Wang, et al., “Ac4C modification of lncRNA SIMALR Promotes Nasopharyngeal Carcinoma Progression Through Activating eEF1A2 to Facilitate ITGB4/ITGA6 Translation,” Oncogene 43, no. 38 (2024): 2868–2884, https://doi.org/10.1038/s41388-024-03133-x.

[173] Z. Xue, H. Xie, Y. Shan, et al., “NAT10 Inhibition Promotes ac4C-Dependent Ferroptosis to Counteract Sorafenib Resistance in Nasopharyngeal Carcinoma,” Cancer Science 115, no. 10 (2024): 3256–3272, https://doi.org/10.1111/cas.16249.

[174] H. Xie, K. Zhang, H. Yin, et al., “Acetyltransferase NAT10 Inhibits T-Cell Immunity and Promotes Nasopharyngeal Carcinoma Progression Through DDX5/HMGB1 Axis,” Journal for ImmunoTherapy of Cancer 13, no. 2 (2025): e010301.

[175] Y. Liu, H. Huang, C. B. Zhang, and H. N. Fan, “N-Acetyltransferase 10 Promotes the Progression of Oral Squamous Cell Carcinoma Through N4-Acetylcytidine RNA Acetylation of MMP1 mRNA,” Cancer Science 114, no. 11 (2023): 4202–4215.

[176] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer Statistics, 2020,” CA: A Cancer Journal for Clinicians 70, no. 1 (2020): 7–30.

[177] J. Liu, Z. Gu, L. Zou, et al., “Acetyltransferase NAT10 Promotes an Immunosuppressive Microenvironment by Modulating CD8+ T Cell Activity in Prostate Cancer,” Molecular Biomedicine 5, no. 1 (2024): 67.

[178] K. J. Li, Y. Hong, Y. Z. Yu, et al., “NAT10 Promotes Prostate Cancer Growth and Metastasis by Acetylating mRNAs of HMGA1 and KRT8,” Advanced Science (Weinheim) 11, no. 32 (2024): e2310131, https://doi.org/10.1002/advs.202310131.

[179] T. Gambichler, F. Breuckmann, S. Boms, P. Altmeyer, and A. Kreuter, “Narrowband UVB Phototherapy in Skin Conditions Beyond Psoriasis,” Journal of the American Academy of Dermatology 52, no. 4 (2005): 660–670.

[180] Z. Yang, E. Wilkinson, Y. H. Cui, H. Li, and Y. Y. He, “NAT10 Regulates the Repair of UVB-Induced DNA Damage and Tumorigenicity,” Toxicology and Applied Pharmacology 477 (2023): 116688.

[181] A. Sancar, L. A. Lindsey-Boltz, K. Unsal-Kaçmaz, and S. Linn, “Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints,” Annual Review of Biochemistry 73 (2004): 39–85.

[182] S. Strashilov and A. Yordanov, “Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances,” International Journal of Molecular Sciences 22, no. 12 (2021): 6395.

[183] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer Statistics, 2018,” CA: A Cancer Journal for Clinicians 68, no. 1 (2018): 7–30.

[184] L. Wang, Y. Zeng, Y. Zhang, Y. Zhu, S. Xu, and Z. Liang, “Acetylcytidine Modification of DDX41 and ZNF746 by N-Acetyltransferase 10 Contributes to Chemoresistance of Melanoma,” Frontiers in Oncology 14 (2024): 1448890.

[185] H. Döhner, D. J. Weisdorf, and C. D. Bloomfield, “Acute Myeloid Leukemia,” New England Journal of Medicine 373, no. 12 (2015): 1136–1152.

[186] S. Zhang, F. Huang, Y. Wang, et al., “NAT10-Mediated mRNA N4-Acetylcytidine Reprograms Serine Metabolism to Drive Leukaemogenesis and Stemness in Acute Myeloid Leukaemia,” Nature Cell Biology 26, no. 12 (2024): 2168–2182, https://doi.org/10.1038/s41556-024-01548-y.

[187] J. Parkin and B. Cohen, “An Overview of the Immune System,” Lancet 357, no. 9270 (2001): 1777–1789.

[188] G. C. Tsokos, M. S. Lo, P. Costa Reis, and K. E. Sullivan, “New Insights Into the Immunopathogenesis of Systemic Lupus Erythematosus,” Nature Reviews Rheumatology 12, no. 12 (2016): 716–730.

[189] A. Wardowska, “The Epigenetic Face of Lupus: Focus on Antigen-Presenting Cells,” International Immunopharmacology 81 (2020): 106262.

[190] G. Guo, X. Shi, H. Wang, et al., “Epitranscriptomic N4-Acetylcytidine Profiling in CD4+ T Cells of Systemic Lupus Erythematosus,” Frontiers in Cell and Developmental Biology 8 (2020): 842.

[191] T. Watanabe, E. Kawakami, J. E. Shoemaker, et al., “Influenza Virus-Host Interactome Screen as a Platform for Antiviral Drug Development,” Cell Host & Microbe 16, no. 6 (2014): 795–805.

[192] Y. Furuse, “RNA Modifications in Genomic RNA of Influenza A Virus and the Relationship Between RNA Modifications and Viral Infection,” International Journal of Molecular Sciences 22, no. 17 (2021): 9127.

[193] H. Hao, W. Liu, Y. Miao, et al., “N4-Acetylcytidine Regulates the Replication and Pathogenicity of Enterovirus 71,” Nucleic Acids Research 50, no. 16 (2022): 9339–9354.

[194] T. Wolf, W. Jin, and G. Zoppi, “Dynamics in Protein Translation Sustaining T Cell Preparedness,” Nature Immunology 21, no. 8 (2020): 927–937.

[195] L. Sun, X. Li, F. Xu, et al., “A Critical Role of N4-Acetylation of Cytidine in mRNA by NAT10 in T Cell Expansion and Antiviral Immunity,” Nature Immunology 26, no. 4 (2025): 619–634, https://doi.org/10.1038/s41590-025-02100-2.

[196] W. Li, D. Li, Y. Chen, et al., “Classic Signaling Pathways in Alveolar Injury and Repair Involved in Sepsis-Induced ALI/ARDS: New Research Progress and Prospect,” Disease Markers 2022 (2022): 6362344.

[197] P. Xing, M. Zhou, J. Sun, D. Wang, W. Huang, and P. An, “NAT10-Mediated ac4C Acetylation of TFRC Promotes Sepsis-Induced Pulmonary Injury Through Regulating Ferroptosis,” Molecular Medicine 30, no. 1 (2024): 140.

[198] H. Zhang, Z. Chen, J. Zhou, et al., “NAT10 Regulates Neutrophil Pyroptosis in Sepsis via Acetylating ULK1 RNA and Activating STING Pathway,” Communications Biology 5, no. 1 (2022): 916.

[199] K. D. Nance, S. T. Gamage, M. M. Alam, et al., “Cytidine Acetylation Yields a Hypoinflammatory Synthetic Messenger RNA,” Cell Chemical Biology 29, no. 2 (2022): 312–320.

[200] J. Atkinson and O. Braddick, “Visual Development,” Handbook in Clinical Neurology 173 (2020): 121–142.

[201] X. Fei, Y. Cai, F. Lin, Y. Huang, T. Liu, and Y. Liu, “Amniotic Fluid Mesenchymal Stem Cells Repair Mouse Corneal Cold Injury by Promoting mRNA N4-Acetylcytidine Modification and ETV4/JUN/CCND2 Signal Axis Activation,” Human Cell 34, no. 1 (2021): 86–98.

[202] H. Zhou, Y. Hu, G. Qin, et al., “The Signature of Serum Modified Nucleosides in Uveitis,” Investigative Ophthalmology & Visual Science 66, no. 2 (2025): 68.

[203] T. Huang, Y. Zhang, Y. Niu, Y. Xiao, Y. Ge, and J. Gao, “The Cytidine N-Acetyltransferase NAT10 Promotes Thalamus Hemorrhage-Induced Central Poststroke Pain by Stabilizing Fn14 Expression in Thalamic Neurons,” Molecular Neurobiology 62, no. 3 (2025): 3276–3292, https://doi.org/10.1007/s12035-024-04454-4.

[204] V. Saini, L. Guada, and D. R. Yavagal, “Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions,” Neurology 97, no. 20 suppl. 2 (2021): S6–S16.

[205] L. Yang, X. Li, Y. Zhao, et al., “NAT10 Inhibition Alleviates Astrocyte Autophagy by Impeding ac4C Acetylation of Timp1 mRNA in Ischemic Stroke,” Acta Pharmaceutica Sinica B 15, no. 5 (2025): 2575–2592, https://doi.org/10.1016/j.apsb.2025.03.042.

[206] Y. H. Kuan, H. C. Shih, S. C. Tang, J. S. Jeng, and B. C. Shyu, “Targeting P(2)X(7) Receptor for the Treatment of Central Post-Stroke Pain in a Rodent Model,” Neurobiology of Disease 78 (2015): 134–145.

[207] M. Broly, B. V. Polevoda, K. M. Awayda, et al., “THUMPD1 Bi-Allelic Variants Cause Loss of tRNA Acetylation and a Syndromic Neurodevelopmental Disorder,” American Journal of Human Genetics 109, no. 4 (2022): 587–600.

[208] R. M. Jamiolkowski, Q. A. Nguyen, J. S. Farrell, et al., “The Fasciola cinereum of the Hippocampal Tail as an Interventional Target in Epilepsy,” Nature Medicine 30, no. 5 (2024): 1292–1299.

[209] N. Renier, E. L. Adams, C. Kirst, et al., “Mapping of Brain Activity by Automated Volume Analysis of Immediate Early Genes,” Cell 165, no. 7 (2016): 1789–1802.

[210] A. Zhang, J. Yang, M. Wang, et al., “Target Inhibition of NAT10-Mediated ac4C Modification Prevents Seizure Behavior in Mice,” Neuropharmacology 272 (2025): 110415.

[211] C. S. Melincovici, A. B. Boşca, S. Şuşman, et al., “Vascular Endothelial Growth Factor (VEGF)—Key Factor in Normal and Pathological Angiogenesis,” Romanian Journal of Morphology and Embryology 59, no. 2 (2018): 455–467.

[212] Z. Peng, F. Yang, S. Huang, Y. Tang, and L. Wan, “Targeting Vascular Endothelial Growth Factor A With Soluble Vascular Endothelial Growth Factor Receptor 1 Ameliorates Nerve Injury-Induced Neuropathic Pain,” Molecular Pain 18 (2022): 17448069221094528.

[213] T. Xu, J. Wang, Y. Wu, et al., “Ac4C Enhances the Translation Efficiency of Vegfa mRNA and Mediates Central Sensitization in Spinal Dorsal Horn in Neuropathic Pain,” Advanced Science (Weinheim) 10, no. 35 (2023): e2303113.

[214] Y. Ma, C. Fan, Y. Wang, W. Li, H. Jiang, and W. Yang, “Comprehensive Analysis of mRNAs in the Cerebral Cortex in APP/PS1 Double-Transgenic Mice With Alzheimer's Disease Based on High-Throughput Sequencing of N4-acetylcytidine,” Functional & Integrative Genomics 23, no. 3 (2023): 267.

[215] Y. Ma, W. Li, C. Fan, Y. Wang, H. Jiang, and W. Yang, “Comprehensive Analysis of Long Non-Coding RNAs N4-Acetylcytidine in Alzheimer's Disease Mice Model Using High-Throughput Sequencing,” Journal of Alzheimer's Disease 90, no. 4 (2022): 1659–1675.

[216] H. N. Ji, H. Q. Zhou, J. B. Qie, W. M. Lu, H. T. Gao, and D. H. Wu, “Dysregulated ac4C Modification of mRNA in a Mouse Model of Early-Stage Alzheimer's Disease,” Cell Bioscience 15, no. 1 (2025): 45.

[217] C. Huo, X. Liu, J. Zhao, T. Zhao, H. Huang, and H. Ye, “Abnormalities in Behaviour, Histology and Prefrontal Cortical Gene Expression Profiles Relevant to Schizophrenia in Embryonic Day 17 MAM-Exposed C57BL/6 Mice,” Neuropharmacology 140 (2018): 287–301.

[218] T. Singh, T. Poterba, D. Curtis, et al., “Rare Coding Variants in Ten Genes Confer Substantial Risk for Schizophrenia,” Nature 604, no. 7906 (2022): 509–516.

[219] L. Xue, J. Zhao, X. Liu, T. Zhao, Y. Zhang, and H. Ye, “MK-801-Exposure Induces Increased Translation Efficiency and mRNA Hyperacetylation of Grin2a in the Mouse Prefrontal Cortex,” Epigenetics 19, no. 1 (2024): 2417158.

[220] L. E. Dorn, S. Tual-Chalot, K. Stellos, and F. Accornero, “RNA Epigenetics and Cardiovascular Diseases,” Journal of Molecular and Cellular Cardiology 129 (2019): 272–280.

[221] M. Bäck, A. Yurdagul, I. Tabas, K. Öörni, and P. T. Kovanen, “Inflammation and Its Resolution in Atherosclerosis: Mediators and Therapeutic Opportunities,” Nature Reviews Cardiology 16, no. 7 (2019): 389–406.

[222] W. Yin, J. Wang, L. Li, H. Zheng, and S. Xu, “NAT10 Modulates Atherosclerosis Progression Mediated by Macrophage Polarization Through Regulating ac4C Modification of TLR9,” Journal of Cardiovascular Translational Research 18, no. 2 (2025): 247–256, https://doi.org/10.1007/s12265-024-10579-7.

[223] K. Wang, L. Y. Zhou, F. Liu, et al., “Piwi-Interacting RNA HAAPIR Regulates Cardiomyocyte Death After Myocardial Infarction by Promoting NAT10-Mediated ac4 C Acetylation of Tfec mRNA,” Advanced Science (Weinheim) 9, no. 8 (2022): e2106058.

[224] J. Shi, C. Yang, J. Zhang, et al., “NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation,” Circulation Research 133, no. 12 (2023): 989–1002.

[225] T. Xu, T. Du, X. Zhuang, et al., “Loss of NAT10 Reduces the Translation of Kmt5a mRNA Through ac4C Modification in Cardiomyocytes and Induces Heart Failure,” Journal of the American Heart Association 13, no. 20 (2024): e035714.

[226] G. L. Basatemur, H. F. Jørgensen, M. C. H. Clarke, M. R. Bennett, and Z. Mallat, “Vascular Smooth Muscle Cells in Atherosclerosis,” Nature Reviews Cardiology 16, no. 12 (2019): 727–744.

[227] C. Yu, Y. Chen, H. Luo, et al., “NAT10 Promotes Vascular Remodelling via mRNA ac4C Acetylation,” European Heart Journal 46, no. 3 (2025): 288–304, https://doi.org/10.1093/eurheartj/ehae707.

[228] K. Thygesen, J. S. Alpert, A. S. Jaffe, et al., “Fourth Universal Definition of Myocardial Infarction (2018),” Journal of the American College of Cardiology 72, no. 18 (2018): 2231–2264.

[229] X. X. Wang, Y. M. Zhao, Q. Y. Zhang, et al., “Acetylcytidine Modification of Amotl1 by N-Acetyltransferase 10 Contributes to Cardiac Fibrotic Expansion in Mice After Myocardial Infarction,” Acta Pharmacologica Sinica 45, no. 7 (2024): 1425–1437.

[230] Z. Qu, X. Pang, Z. Mei, et al., “The Positive Feedback Loop of the NAT10/Mybbp1a/p53 Axis Promotes Cardiomyocyte Ferroptosis to Exacerbate Cardiac I/R Injury,” Redox Biology 72 (2024): 103145.

[231] Y. Hao, B. Li, F. Yin, and W. Liu, “tRNA-Derived Small RNA (tsr007330) Regulates Myocardial Fibrosis After Myocardial Infarction Through NAT10-Mediated ac4C Acetylation of EGR3 mRNA,” Biochimica et Biophysica Acta Molecular Basis of Disease 1870, no. 6 (2024): 167267.

[232] X. Jiang, Y. Cheng, Y. Zhu, et al., “Maternal NAT10 Orchestrates Oocyte Meiotic Cell-Cycle Progression and Maturation in Mice,” Nature Communications 14, no. 1 (2023): 3729.

[233] L. Chen, W. J. Wang, S. Y. Liu, et al., “NAT10-Mediated mRNA N4-Acetylation Is Essential for the Translational Regulation During Oocyte Meiotic Maturation in Mice,” Science Advances 11, no. 8 (2025): eadp5163.

[234] L. Chen, W. J. Wang, Q. Liu, et al., “NAT10-Mediated N4-Acetylcytidine Modification Is Required for Meiosis Entry and Progression in Male Germ Cells,” Nucleic Acids Research 50, no. 19 (2022): 10896–10913.

[235] T. S. Barakat, F. Halbritter, M. Zhang, et al., “Functional Dissection of the Enhancer Repertoire in Human Embryonic Stem Cells,” Cell Stem Cell 23, no. 2 (2018): 276–288.

[236] J. Ge, Z. Wang, and J. Wu, “NAT10-Mediated ac4C Modification Promotes Ectoderm Differentiation of Human Embryonic Stem Cells via Acetylating NR2F1 mRNA,” Cell Proliferation 57, no. 4 (2024): e13577.

[237] P. Zheng, N. Li, and X. Zhan, “Ovarian Cancer Subtypes Based on the Regulatory Genes of RNA Modifications: Novel Prediction Model of Prognosis,” Frontiers in Endocrinology (Lausanne) 13 (2022): 972341.

[238] Z. Nash and M. Davies, “Premature Ovarian Insufficiency,” BMJ 384 (2024): e077469.

[239] R. Zhang, L. Lao, K. Ren, and B. M. Berman, “Mechanisms of Acupuncture-Electroacupuncture on Persistent Pain,” Anesthesiology 120, no. 2 (2014): 482–503.

[240] Z. Geng, P. Liu, L. Yuan, et al., “Electroacupuncture Attenuates ac4C Modification of P16 mRNA in the Ovarian Granulosa Cells of a Mouse Model Premature Ovarian Failure,” Acupuncture in Medicine 41, no. 1 (2023): 27–37.

[241] W. Zhang, J. Zhang, Y. Zhang, et al., “The Up-Regulation of RIPK3 Mediated by ac4C Modification Promotes Oxidative Stress-Induced Granulosa Cell Senescence by Inhibiting the Nrf2/HO-1 Pathway,” IUBMB Life 77, no. 1 (2025): e2944, https://doi.org/10.1002/iub.2944.

[242] R. O. Burney and L. C. Giudice, “Reprint of: Pathogenesis and Pathophysiology of Endometriosis,” Fertility and Sterility 112, no. 4 suppl. 1 (2019): e153–e161.

[243] N. Liu, J. YangOu, C. Wei, et al., “NAT10 Drives Endometriosis Progression Through Acetylation and Stabilization of TGFB1 mRNA,” Molecular and Cellular Endocrinology 597 (2025): 112447.

[244] T. J. Martin and E. Seeman, “New Mechanisms and Targets in the Treatment of Bone Fragility,” Clinical Science (London) 112, no. 2 (2007): 77–91.

[245] D. V. Novack and G. Mbalaviele, “Osteoclasts-Key Players in Skeletal Health and Disease,” Microbiology Spectrum 4, no. 3 (2016): 1–19, https://doi.org/10.1128/microbiolspec.MCHD-0011-2015.

[246] R. Yang, W. Yu, L. Lin, et al., “NAT10 Promotes Osteoclastogenesis in Inflammatory Bone Loss by Catalyzing Fos mRNA ac4C Modification and Upregulating MAPK Signaling Pathway,” Journal of Advanced Research 72 (2025): 303–317, https://doi.org/10.1016/j.jare.2024.07.031.

[247] W. Yang, H. Y. Li, Y. F. Wu, et al., “ac4C acetylation of RUNX2 Catalyzed by NAT10 Spurs Osteogenesis of BMSCs and Prevents Ovariectomy-Induced Bone Loss,” Molecular Therapy—Nucleic Acids 26 (2021): 135–147.

[248] Z. Cui, Y. Xu, P. Wu, et al., “NAT10 Promotes Osteogenic Differentiation of Periodontal Ligament Stem Cells by Regulating VEGFA-Mediated PI3K/AKT Signaling Pathway Through ac4C Modification,” Odontology 111, no. 4 (2023): 870–882.

[249] Y. Feng, T. Zhang, and Y. Chang, “Compression Force Promotes the Osteogenic Differentiation of Periodontal Ligament Stem Cells by Regulating NAT10-Mediated ac4C Modification of BMP2,” Journal of Orthopaedic Surgery and Research 19, no. 1 (2024): 861.

[250] D. Xiao, S. Huang, Z. Tang, et al., “Mijiao Formula Regulates NAT10-Mediated Runx2 mRNA ac4C Modification to Promote Bone Marrow Mesenchymal Stem Cell Osteogenic Differentiation and Improve Osteoporosis in Ovariectomized Rats,” Journal of Ethnopharmacology 330 (2024): 118191.

[251] Z. Zhang, Y. Zhang, Y. Cai, et al., “NAT10 Regulates the LPS-Induced Inflammatory Response via the NOX2-ROS-NF-κB Pathway in Macrophages,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research 1870, no. 7 (2023): 119521.

[252] M. H. Smith and J. R. Berman, “What Is Rheumatoid Arthritis?,” JAMA 327, no. 12 (2022): 1194.

[253] D. Liu, Y. Kuang, S. Chen, et al., “NAT10 Promotes Synovial Aggression by Increasing the Stability and Translation of N4-Acetylated PTX3 mRNA in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 83, no. 9 (2024): 1118–1131.

[254] American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care 47, no. suppl. 1(2024): S20–S42.

[255] S. T. Gamage, R. Khoogar, S. H. Manage, et al., “Transfer RNA Acetylation Regulates In Vivo Mammalian Stress Signaling,” BioRxiv, https://doi.org/10.1101/2024.07.25.605208, Published online July 28, 2024:2024.07.25.605208.

[256] C. L. Hsu and R. Loomba, “From NAFLD to MASLD: Implications of the New Nomenclature for Preclinical and Clinical Research,” Nature Metabolism 6, no. 4 (2024): 600–602.

[257] G. Feng, L. Valenti, V. W. S. Wong, et al., “Recompensation in Cirrhosis: Unravelling the Evolving Natural History of Nonalcoholic Fatty Liver Disease,” Nature Reviews Gastroenterology & Hepatology 21, no. 1 (2024): 46–56.

[258] Z. Wang, X. Wan, M. A. Khan, et al., “NAT10 Promotes Liver Lipogenesis in Mouse Through N4-Acetylcytidine Modification of Srebf1 and Scap mRNA,” Lipids Health Disease 23, no. 1 (2024): 368.

[259] A. Lonardo, A. Mantovani, S. Petta, A. Carraro, C. D. Byrne, and G. Targher, “Metabolic Mechanisms for and Treatment of NAFLD or NASH Occurring After Liver Transplantation,” Nature Reviews Endocrinology 18, no. 10 (2022): 638–650.

[260] S. Hendrix, J. Kingma, R. Ottenhoff, et al., “Hepatic SREBP Signaling Requires SPRING to Govern Systemic Lipid Metabolism in Mice and Humans,” Nature Communications 14, no. 1 (2023): 5181.

[261] Y. Yang, J. Lu, Y. Liu, et al., “Improvement of MASLD and MASH by Suppression of Hepatic N-Acetyltransferase 10,” Molecular Metabolism 89 (2024): 102030.

[262] L. Richeldi, H. R. Collard, and M. G. Jones, “Idiopathic Pulmonary Fibrosis,” Lancet 389, no. 10082 (2017): 1941–1952.

[263] W. Shenshen, L. Yin, K. Han, et al., “NAT10 Accelerates Pulmonary Fibrosis Through N4-Acetylated TGFB1-Initiated Epithelial-to-Mesenchymal Transition Upon Ambient Fine Particulate Matter Exposure,” Environmental Pollution 322 (2023): 121149.

[264] K. Bisht, J. Baishya, and C. A. Wakeman, “Pseudomonas aeruginosa Polymicrobial Interactions During Lung Infection,” Current Opinion in Microbiology 53 (2020): 1–8.

[265] M. Huang, J. Li, J. Bai, X. Du, and J. Xu, “NAT10 Induces Mitochondrial Dysfunction in Lung Epithelial Cells by Acetylating HMGB1 to Exacerbate Pseudomonas aeruginosa-Induced Acute Lung Injury,” Microbial Pathogenesis 200 (2025): 107364.

[266] L. P. Bruner, A. M. White, and S. Proksell, “Inflammatory Bowel Disease,” Primary Care 50, no. 3 (2023): 411–427.

[267] H. Li, X. Cai, C. Xu, et al., “RNA Cytidine Acetyltransferase NAT10 Maintains T Cell Pathogenicity in Inflammatory Bowel Disease,” Cell Discovery 11, no. 1 (2025): 19.

[268] P. K. Garg and V. P. Singh, “Organ Failure due to Systemic Injury in Acute Pancreatitis,” Gastroenterology 156, no. 7 (2019): 2008–2023.

[269] K. Gao, X. Yang, W. Zhao, Y. Lin, B. Hu, and D. Wang, “NAT10 Promotes Pyroptosis and Pancreatic Injury of Severe Acute Pancreatitis Through ac4C Modification of NLRP3,” Shock 63, no. 5 (2025): 774–780, https://doi.org/10.1097/SHK.0000000000002551.

[270] M. Deng, L. Zhang, W. Zheng, et al., “Helicobacter pylori-Induced NAT10 Stabilizes MDM2 mRNA via RNA Acetylation to Facilitate Gastric Cancer Progression,” Journal of Experimental & Clinical Cancer Research 42, no. 1 (2023): 9.

[271] J. Wang, X. Li, W. Qubi, et al., “The Important Role of m6A-Modified circRNAs in the Differentiation of Intramuscular Adipocytes in Goats Based on MeRIP Sequencing Analysis,” International Journal of Molecular Sciences 24, no. 5 (2023): 4817.

[272] H. Weng, H. Huang, H. Wu, et al., “METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification,” Cell Stem Cell 22, no. 2 (2018): 191–205.

[273] X. Liu, Y. Tan, C. Zhang, et al., “NAT10 Regulates p53 Activation Through Acetylating p53 at K120 and Ubiquitinating Mdm2,” EMBO Reports 17, no. 3 (2016): 349–366.

[274] J. L. Meier, “Metabolic Mechanisms of Epigenetic Regulation,” ACS Chemical Biology 8, no. 12 (2013): 2607–2621.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.